SciSparc Ltd. has taken a significant step in its capital-raising efforts by filing a registration statement with the Securities and Exchange Commission (SEC) to offer up to 76,807,229 ordinary shares. This move is crucial for the company as it seeks to enhance its financial flexibility and support its ongoing development programs in cannabinoid therapies.

The filing, dated November 9, 2026, indicates that the shares will be offered through a resale arrangement by a selling shareholder. The company has outlined that it may issue and sell convertible promissory notes to the selling shareholder, which can convert into ordinary shares, further expanding its capital base.

SciSparc Ltd., incorporated in Israel, operates in the pharmaceutical preparations sector, specifically focusing on cannabinoid-based therapies. The company is known for its innovative approach to treating conditions like Tourette syndrome and Alzheimer’s disease through its drug candidates, SCI-110 and SCI-210. The filing aligns with the company's strategy to leverage its unique position in a rapidly evolving industry.

Background

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company that develops cannabinoid therapies. The company is listed on the Nasdaq under the ticker SPRC and is classified under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. Recent filings include a Form 6-K/A and a Form 6-K, both filed on November 9, 2026, indicating ongoing activity and engagement with investors.

What the Filing Says

The registration statement filed by SciSparc states, "This prospectus relates to the resale, by the selling shareholder... of up to 76,807,229 ordinary shares..." This highlights the company's plan to facilitate the sale of shares that may be converted from promissory notes and warrants, providing liquidity for the selling shareholder while potentially raising capital for the company.

Impact

This filing could significantly affect existing shareholders and potential investors. By increasing the number of shares available in the market, it may lead to dilution of existing shares but also provides an opportunity for the company to raise funds necessary for its development programs. The filing indicates that the company is actively seeking to enhance its financial position, which could be beneficial for its long-term growth.

What's Next

The filing does not specify what happens next regarding the timing of the share offering or any further steps in the capital-raising process. However, it is clear that the company is preparing for future transactions that could shape its financial landscape.